Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Blood Test with Potential to Detect Stage One Cancer

Published: Tuesday, October 23, 2012
Last Updated: Tuesday, October 23, 2012
Bookmark and Share
Soricimed Biopharma Inc. announced that a pre-regulatory study of their blood test for early detection and diagnosis of cancer has commenced.

Soricimed developed their blood test to detect the presence of TRPV6 messenger RNA, a biomarker identified as being present in many epithelially derived cancers. The test has been shown to detect a host of cancers, including ovarian, breast and prostate, at their earliest stages.

Working in partnership with the Dr. Georges-L.-Dumont University Hospital Centre, a member institution of the Vitalite Health Network, located in Moncton, NB, Soricimed has initiated a blood sampling project to collect samples from up to 700 patients.

"We have been able to isolate a marker from human blood plasma which, in cancer patients, shows a fingerprint of the cancer", commented Professor Jack Stewart, Chief Scientific Officer at Soricimed Biopharma. "It's like an early warning system that alerts physicians to the presence of cancer."

"Half the battle with cancer is being able to detect it early enough to save lives", stated Elisabeth Ross, Chief Executive Officer, Ovarian Cancer Canada. "In the case of ovarian cancer, there are no early symptoms and currently no screening tests available so it's not usually detected until Stage Three or Four. As a result, the mortality rate is extremely high, with - 70% of women not surviving more than five years. If ovarian cancer could be detected at Stage One, we could dramatically increase survival rates."

"We are thrilled to be part of the research continuum that moves novel discoveries into the clinical practice, in hopes of improving the health outcomes of our population. The success of this project is the result of a great collaboration with Soricimed Biopharma Inc., our clinicians and multidisciplinary teams at the Dr. Georges-L.-Dumont University Hospital Centre", stated Gilles Beaulieu, Vice-President, Academic Affairs and Research at Vitalite Health Network.

The study is expected to be completed late Fall of this year. Based on successful results, Soricimed Biopharma would move the test through the regulatory approval process which could result in an approved diagnostic being available for use within 24 months. Testing for cancer could become just another box to check on a person's regular physical examination.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Making Virus Sensors Cheap and Simple
Researchers at The University of Texas at Austin demonstrated the ability to detect single viruses in a solution containing murine cytomegalovirus (MCMV).
Heart Defect Prediction Technology Could Lead to Earlier, More Informed Treatment
Experimental method uses genetics-guided biomechanics, patient-specific stem cells.
Biosensor Detects Molecules Linked to Cancer, Alzheimer's and Parkinson's
Novel biosensor has been proven capable of detecting molecules associated with neurodegenerative diseases and some types of cancer.
Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
Fast, Simple Test for Colitis
A minimally invasive screening for ulcerative colitis using emerging infrared technology could be a rapid and cost-effective method for detecting disease that eliminates the need for biopsies and intrusive testing of the human body.
Scans Reveal Babies of Mothers with Gestational Diabetes Have More Body Fat
Researchers at Imperial College London have found that the babies born to mothers with gestational diabetes have more body fat at two months of age compared to babies born to healthy mothers.
New Device Could Improve Cancer Detection
UBC researchers develop a microfluidic device to capture circulating tumor cells.
Plasma Biomarkers for Breast Cancer Diagnosis
Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
Newborn Screening Test Developed For Rare, Deadly Neurological Disorder
Scientists have developed a new dried blood spot screening test for Niemann-Pick type C, with goal to speed diagnosis and treatment.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!